Environmentally responsive peptides as anticancer drug carriers

Advanced Drug Delivery Reviews

Volumn 61, Issue 11, 2009, Pages 940-952

  Aluri, Suhaas ^a   Janib, Siti M ^a   Mackay, J Andrew ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cancer; Chemotherapy; Drug delivery; EPR; Hyperthermia; Peptides; pH; Redox; Tumor

Indexed keywords

ANTICANCER DRUG; CANCER; EPR; FUNCTIONAL UNITS; HYPERTHERMIA; NANOCARRIERS; REDOX; SINGLE POLYMERS; SPECIFIC INTERACTION; TUMOR MICROENVIRONMENT;

BIOCHEMISTRY; BIODEGRADABLE POLYMERS; BIODEGRADATION; CHEMOTHERAPY; DISEASE CONTROL; DRUG DELIVERY; ELECTRON RESONANCE; ELECTRON SPIN RESONANCE SPECTROSCOPY; FUNCTIONAL POLYMERS; PARAMAGNETIC RESONANCE; PEPTIDES; QUANTUM THEORY; TUMORS;

AMINES;

ALBUMIN; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; ASPARAGINYLGLYCYLARGININE; CELL PENETRATING PEPTIDE; COLLAGEN; DOXORUBICIN; DRUG CARRIER; ELASTIN; FOLATE RECEPTOR; GEMTUZUMAB OZOGAMICIN; LEUCINE ZIPPER PROTEIN; LIGAND; LIPOSOME; MITOMYCIN C; MOMORDIN; PACLITAXEL; PEPTIDE; PHOSPHATIDYLETHANOLAMINE; POLYHISTIDINE; POLYPEPTIDE; SILK LIKE POLYPEPTIDE; TRANSFERRIN; TRASTUZUMAB; TRIPEPTIDE; TRYPTOPHANYLGLUTAMYLALANYLALANYLLEUCYLALANYLGLUTAMYLALANYLLEUCYLALANYLGLUTAMYLALANYLLEUCYLALANYLGLUTAMYLHISTIDYLLEUCYLALANYLGLUTAMYLALANYLLEUCYLALANYLGLUTAMYLALANYLLEUCYLGLUTAMYLALANYLLEUCYLALANYLALANINE; TRYPTOPHANYLGLUTAMYLALANYLLYSYLLEUCYLALANYLLYSYLALANYLLEUCYLALANYLLYSYLALANYLLEUCYLALANYLLYSYLHISTIDYLLEUCYLALANYLLYSYLALANYLLEUCYLALANYLLYSYLALANYLLEUCYLLYSYLALANYLCYSTEINYLGLUTAMYLALANINE; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD VESSEL PERMEABILITY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG HYPERSENSITIVITY; DRUG RELEASE; ENDOCYTOSIS; HIGH TEMPERATURE; HUMAN; LIGAND BINDING; MICROENVIRONMENT; OXIDATION REDUCTION REACTION; PH; PRIORITY JOURNAL; PROTEIN MOTIF; RECEPTOR BINDING; REVIEW; TEMPERATURE DEPENDENCE; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; DRUG CARRIERS; HYDROGEN-ION CONCENTRATION; LIGANDS; OXIDATION-REDUCTION; PEPTIDES; PERMEABILITY; TEMPERATURE;

EID: 70349470979     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.07.002     Document Type: Review

References (154)

1. American Cancer Society. Cancer Facts & Figures (2008)
2. Chabner B., and Longo D.L. Cancer Chemotherapy and Biotherapy: Principles and Practice (2001), Lippincott Williams & Wilkins
3. Olson R.D., Boerth R.C., Gerber J.G., and Nies A.S. Mechanism of adriamycin cardiotoxicity: evidence for oxidative stress. Life Sci. 29 (1981) 1393-1401
4. Di Marco A., Gaetani M., and Scarpinato B. Adriamycin (NSC-123,127): a new antibiotic with antitumor activity. Cancer Chemother. Rep. 53 (1969) 33-37
5. Seidman A.D., Hudis C.A., Albanell J., Tong W., Tepler I., Currie V., Moynahan M.E., Theodoulou M., Gollub M., Baselga J., and Norton L. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J. Clin. Oncol. 16 (1998) 3353-3361
6. Vokes E.E., and Golomb H.M. Oncologic Therapies (2003), Springer
7. Schilsky R.L., Milano G.R.A., and Ratain M.J. Principles of Antineoplastic Drug Development and Pharmacology (1996), Dekker
8. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., and Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51 (1999) 691-744
9. Allen T.M., and Cullis P.R. Drug delivery systems: entering the mainstream. Science 303 (2004) 1818-1822
10. Lee C.C., MacKay J.A., Frechet J.M., and Szoka F.C. Designing dendrimers for biological applications. Nat. Biotechnol. 23 (2005) 1517-1526
11. Wong H.L., Bendayan R., Rauth A.M., Li Y., and Wu X.Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 59 (2007) 491-504
12. Henderson I.C., and Bhatia V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev. Anticancer Ther. 7 (2007) 919-943
13. Ranson M.R., Cheeseman S., White S., and Margison J. Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. Crit. Rev. Oncol. Hematol. 37 (2001) 115-120
14. Hawkins M.J., Soon-Shiong P., and Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv. Drug Deliv. Rev. 60 (2008) 876-885
15. Gabizon A., Goren D., Cohen R., and Barenholz Y. Development of liposomal anthracyclines: from basics to clinical applications. J. Control. Release 53 (1998) 275-279
16. Kong G., Anyarambhatla G., Petros W.P., Braun R.D., Colvin O.M., Needham D., and Dewhirst M.W. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res. 60 (2000) 6950-6957
17. Gerweck L.E., and Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res. 56 (1996) 1194-1198
18. Cook J.A., Gius D., Wink D.A., Krishna M.C., Russo A., and Mitchell J.B. Oxidative stress, redox, and the tumor microenvironment. Semin. Radiat. Oncol. 14 (2004) 259-266
19. Mbeunkui F., and Johann Jr. D.J. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother. Pharmacol. 63 (2009) 571-582
20. Schafer F.Q., and Buettner G.R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med. 30 (2001) 1191-1212
21. Ferrara N., Hillan K.J., Gerber H.-P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3 (2004) 391-400
22. Laye J.P., and Gill J.H. Phospholipase A2 expression in tumours: a target for therapeutic intervention?. Drug Discov. Today 8 (2003) 710-716
23. Cummings B.S. Phospholipase A2 as targets for anti-cancer drugs. Biochem. Pharmacol. 74 (2007) 949-959
24. Shen Y., Tang H., Radosz M., Van Kirk E., and Murdoch W.J. pH-responsive nanoparticles for cancer drug delivery. Methods Mol. Biol. 437 (2008) 183-216
25. Tanaka T., Shiramoto S., Miyashita M., Fujishima Y., and Kaneo Y. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int. J. Pharm. 277 (2004) 39-61
26. Dreher M.R., Simnick A.J., Fischer K., Smith R.J., Patel A., Schmidt M., and Chilkoti A. Temperature triggered self-assembly of polypeptides into multivalent spherical micelles. J. Am. Chem. Soc. 130 (2008) 687-694
27. Dreher M.R., Liu W., Michelich C.R., Dewhirst M.W., and Chilkoti A. Thermal cycling enhances the accumulation of a temperature-sensitive biopolymer in solid tumors. Cancer Res. 67 (2007) 4418-4424
28. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
29. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65 (2000) 271-284
30. Yuan F., Leunig M., Huang S.K., Berk D.A., Papahadjopoulos D., and Jain R.K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54 (1994) 3352-3356
31. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., and Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55 (1995) 3752-3756
32. Ahmed M., Lukyanov A.N., Torchilin V., Tournier H., Schneider A.N., and Goldberg S.N. Combined radiofrequency ablation and adjuvant liposomal chemotherapy: effect of chemotherapeutic agent, nanoparticle size, and circulation time. J. Vasc. Interv. Radiol. 16 (2005) 1365-1371
33. Kong G., Braun R.D., and Dewhirst M.W. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res. 60 (2000) 4440-4445
34. Schroeder T., Yuan H., Viglianti B.L., Peltz C., Asopa S., Vujaskovic Z., and Dewhirst M.W. Spatial heterogeneity and oxygen dependence of glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat. Cancer Res. 65 (2005) 5163-5171
35. Saeki T., Tsuruo T., Sato W., and Nishikawsa K. Drug resistance in chemotherapy for breast cancer. Cancer Chemother. Pharmacol. 56 Suppl 1 (2005) 84-89
36. Balendiran G.K., Dabur R., and Fraser D. The role of glutathione in cancer. Cell Biochem. Funct. 22 (2004) 343-352
37. Stavrovskaya A.A. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 65 (2000) 95-106
38. Niitsu Y., Kohgo Y., Nishisato T., Kondo H., Kato J., Urushizaki Y., and Urushizaki I. Transferrin receptors in human cancerous tissues. Tohoku J. Exp. Med. 153 (1987) 239-243
39. Qian Z.M., Li H., Sun H., and Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 54 (2002) 561-587
40. Tanaka T., Fujishima Y., and Kaneo Y. Receptor mediated endocytosis and cytotoxicity of transferrin-mitomycin c conjugate in the HepG2 cell and primary cultured rat hepatocyte. Biol. Pharm. Bull. 24 (2001) 268-273
41. Hilgenbrink A.R., and Low P.S. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J. Pharm. Sci. 94 (2005) 2135-2146
42. Lu Y.J., and Low P.S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev. 54 (2002) 675-693
43. Leamon C.P., and Low P.S. Cytotoxicity of momordin-folate conjugates in cultured human-cells. J. Biol. Chem. 267 (1992) 24966-24971
44. Leamon C.P., and Low P.S. Selective targeting of malignant-cells with cytotoxin-folate conjugates. J. Drug Target. 2 (1994) 101-112
45. Leamon C.P., and Reddy J.A. Folate-targeted chemotherapy. Adv. Drug Deliv. Rev. 56 (2004) 1127-1141
46. Lee R.J., and Huang L. Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer. J. Biol. Chem. 271 (1996) 8481-8487
47. Lee R.J., and Low P.S. Folate-mediated tumor-cell targeting of liposome-entrapped doxorubicin in-vitro. Biochim. Biophys. Acta 1233 (1995) 134-144
48. Cho K.C., Jeong J.H., Chung H.J., Joe C.O., Kim S.W., and Park T.G. Folate receptor-mediated intracellular delivery of recombinant caspase-3 for inducing apoptosis. J. Control. Release 108 (2005) 121-131
49. Song S., Liu D., Peng J., Sun Y., Li Z., Gu J.R., and Xu Y. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int. J. Pharm. 363 (2008) 155-161
50. Wartlick H., Michaelis K., Balthasar S., Strebhardt K., Kreuter J., and Langer K. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J. Drug Target. 12 (2004) 461-471
51. Li Z., Zhao R., Wu X., Sun Y., Yao M., Li J., Xu Y., and Gu J. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. Faseb J. 19 (2005) 1978-1985
52. Mathias C.J., Wang S., Lee R.J., Waters D.J., Low P.S., and Green M.A. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J. Nucl. Med. 37 (1996) 1003-1008
53. Wadia J.S., and Dowdy S.F. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv. Drug Deliv. Rev. 57 (2005) 579-596
54. Hamann P.R., Hinman L.M., Hollander I., Beyer C.F., Lindh D., Holcomb R., Hallett W., Tsou H.R., Upeslacis J., Shochat D., Mountain A., Flowers D.A., and Bernstein I. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. 13 (2002) 47-58
55. Saito G., Swanson J.A., and Lee K.D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv. Drug Deliv. Rev. 55 (2003) 199-215
56. Gillies E.R., Goodwin A.P., and Frechet J.M.J. Acetals as pH-sensitive linkages for drug delivery. Bioconjug. Chem. 15 (2004) 1254-1263
57. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 108 (2005) 171-183
58. Kratz F., Abu Ajaj K., and Warnecke A. Anticancer carrier-linked prodrugs in clinical trials. Expert Opin. Investig. Drugs 16 (2007) 1037-1058
59. Desai N., Trieu V., Yao Z., Louie L., Ci S., Yang A., Tao C., De T., Beals B., Dykes D., Noker P., Yao R., Labao E., Hawkins M., and Soon-Shiong P. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 12 (2006) 1317-1324
60. Hisae Iinuma K.M., Okinaga K., Sasaki K., Sekine T., Ishida O., Ogiwara N., Johkura K., and Yonemura Y. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int. J. Cancer 99 (2002) 130-137
61. Suzuki S., Inoue K., Hongoh A., Hashimoto Y., and Yamazoe Y. Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferrin receptor. Br. J. Cancer 76 (1997) 83-89
62. Huwyler J., Yang J., and Pardridge W.M. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. J. Pharmacol. Exp. Ther. 282 (1997) 1541-1546
63. Chang J.C. HER2 inhibition: from discovery to clinical practice. Clin. Cancer Res. 13 (2007) 1-3
64. Park J.W., Kirpotin D.B., Hong K., Shalaby R., Shao Y., Nielsen U.B., Marks J.D., Papahadjopoulos D., and Benz C.C. Tumor targeting using anti-her2 immunoliposomes. J. Control. Release 74 (2001) 95-113
65. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., Marks J.D., Benz C.C., and Park J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66 (2006) 6732-6740
66. Temming K., Schiffelers R.M., Molema G., and Kok R.J. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist. Updat. 8 (2005) 381-402
67. Mitra A., Mulholland J., Nan A., McNeill E., Ghandehari H., and Line B.R. Targeting tumor angiogenic vasculature using polymer-RGD conjugates. J. Control. Release 102 (2005) 191-201
68. Holig P., Bach M., Volkel T., Nahde T., Hoffmann S., Muller R., and Kontermann R.E. Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells. Protein Eng. Des. Sel. 17 (2004) 433-441
69. Ruoslahti E. Targeting tumor vasculature with homing peptides from phage display. Semin. Cancer Biol. 10 (2000) 435-442
70. Arap W., Pasqualini R., and Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279 (1998) 377-380
71. Corti A., Curnis F., Arap W., and Pasqualini R. The neovasculature homing motif NGR: more than meets the eye. Blood 112 (2008) 2628-2635
72. Schmid B., Chung D.E., Warnecke A., Fichtner I., and Kratz F. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjug. Chem. 18 (2007) 702-716
73. Rejmanova P., Kopecek J., Duncan R., and Lloyd J.B. Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl) methacrylamide copolymers. Biomaterials 6 (1985) 45-48
74. Verma R.P., and Hansch C. Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorg. Med. Chem. 15 (2007) 2223-2268
75. Tauro J.R., and Gemeinhart R.A. Matrix metalloprotease triggered delivery of cancer chemotherapeutics from hydrogel matrixes. Bioconjug. Chem. 16 (2005) 1133-1139
76. Sarkar N., Banerjee J., Hanson A.J., Elegbede A.I., Rosendahl T., Krueger A.B., Banerjee A.L., Tobwala S., Wang R., Lu X., Mallik S., and Srivastava D.K. Matrix metalloproteinase-assisted triggered release of liposomal contents. Bioconjug. Chem. 19 (2008) 57-64
77. Sawaya R.E., Yamamoto M., Gokaslan Z.L., Wang S.W., Mohanam S., Fuller G.N., McCutcheon I.E., Stetler-Stevenson W.G., Nicolson G.L., and Rao J.S. Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin. Exp. Metastasis 14 (1996) 35-42
78. Forsyth P.A., Wong H., Laing T.D., Rewcastle N.B., Morris D.G., Muzik H., Leco K.J., Johnston R.N., Brasher P.M., Sutherland G., and Edwards D.R. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br. J. Cancer 79 (1999) 1828-1835
79. Nagase H., and Fields G.B. Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides. Pept. Sci. 40 (1996) 399-416
80. Han H.D., Choi M.S., Hwang T., Song C.K., Seong H., Kim T.W., Choi H.S., and Shin B.C. Hyperthermia-induced antitumor activity of thermosensitive polymer modified temperature-sensitive liposomes. J. Pharm. Sci. 95 (2006) 1909-1917
81. Baronzio G.F., and Hager E.D. Hyperthermia in cancer treatment a primer. Landes Biosci. (2006)
82. Gerweck L.E. Hyperthermia in cancer therapy: the biological basis and unresolved questions. Cancer Res. 45 (1985) 3408-3414
83. M.S.K. Chang W. Song, Juong G. Rhee, Seymour H. Levitt, Effect of hyperthermia on vascular function in normal and neoplastic tissues, Ann N Y Acad Sci. 335 (1980) 35-47.
84. Kennedy J.E. High-intensity focused ultrasound in the treatment of solid tumours. Nat. Rev., Cancer 5 (2005) 321-327
85. Gupta A.K., Naregalkar R.R., Vaidya V.D., and Gupta M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomedicine 2 (2007) 23-39
86. Meyer D.E., Kong G.A., Dewhirst M.W., Zalutsky M.R., and Chilkoti A. Targeting a genetically engineered elastin-like polypeptide to solid tumors by local hyperthermia. Cancer Res. 61 (2001) 1548-1554
87. Yatvin M.B., Weinstein J.N., Dennis W.H., and Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science 202 (1978) 1290-1293
88. Kono K. Thermosensitive polymer-modified liposomes. Adv. Drug Deliv. Rev. 53 (2001) 307-319
89. Mackay J.A., and Chilkoti A. Temperature sensitive peptides: engineering hyperthermia-directed therapeutics. Int. J. Hypertherm. 24 (2008) 483-495
90. Meyer D.E., Shin B.C., Kong G.A., Dewhirst M.W., and Chilkoti A. Drug targeting using thermally responsive polymers and local hyperthermia. J. Control. Release 74 (2001) 213-224
91. Mart R.J., Osborne R.D., Stevens M.M., and Ulijn R.V. Peptide-based stimuli-responsive biomaterials. Soft Matter 2 (2006) 822-835
92. Hart D.S., and Gehrke S.H. Thermally associating polypeptides designed for drug delivery produced by genetically engineered cells. J. Pharm. Sci. 96 (2007) 484-516
93. Petka W.A., Harden J.L., McGrath K.P., Wirtz D., and Tirrell D.A. Reversible hydrogels from self-assembling artificial proteins. Science 281 (1998) 389-392
94. Xu C., Breedveld V., and Kopecek J. Reversible hydrogels from self-assembling genetically engineered protein block copolymers. Biomacromolecules 6 (2005) 1739-1749
95. Urry D.W. Physical chemistry of biological free energy transduction as demonstrated by elastic protein-based polymers. J. Phys. Chem. B 101 (1997) 11007-11028
96. Dreher M.R., Simnick A.J., Fischer K., Smith R.J., Patel A., Schmidt M., and Chilkoti A. Temperature triggered self-assembly of polypeptides into multivalent spherical micelles. J. Am. Chem. Soc. 130 (2008) 687-694
97. Dreher M.R., Raucher D., Balu N., Michael Colvin O., Ludeman S.M., and Chilkoti A. Evaluation of an elastin-like polypeptide-doxorubicin conjugate for cancer therapy. J. Control. Release 91 (2003) 31-43
98. Bidwell III G.L., Davis A.N., Fokt I., Priebe W., and Raucher D. A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance. Invest New. Drugs 25 (2007) 313-326
99. Bidwell III G.L., Fokt I., Priebe W., and Raucher D. Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin. Biochem. Pharmacol. 73 (2007) 620-631
100. Gil E.S., Frankowski D.J., Spontak R.J., and Hudson S.M. Swelling behavior and morphological evolution of mixed gelatin/silk fibroin hydrogels. Biomacromolecules 6 (2005) 3079-3087
101. Megeed Z., Cappello J., and Ghandehari H. Genetically engineered silk-elastinlike protein polymers for controlled drug delivery. Adv. Drug Deliv. Rev. 54 (2002) 1075-1091
102. Stoica F., Alexander C., Tirelli N., Miller A.F., and Saiani A. Selective synthesis of double temperature-sensitive polymer-peptide conjugates. Chem. Commun. (Camb) (2008) 4433-4435
103. Collier J.H., Hu B.H., Ruberti J.W., Zhang J., Shum P., Thompson D.H., and Messersmith P.B. Thermally and photochemically triggered self-assembly of peptide hydrogels. J. Am. Chem. Soc. 123 (2001) 9463-9464
104. Chaiswing L., Zhong W., Cullen J.J., Oberley L.W., and Oberley T.D. Extracellular redox state regulates features associated with prostate cancer cell invasion. Cancer Res. 68 (2008) 5820-5826
105. Meister A., and Anderson M.E. Glutathione. Annu. Rev. Biochem. 52 (1983) 711-760
106. Miyazaki K., Noda N., Okada S., Hagiwara Y., Miyata M., Sakurabayashi I., Yamaguchi N., Sugimura T., Terada M., and Wakasugi H. Elevated serum level of thioredoxin in patients with hepatocellular carcinoma. Biotherapy 11 (1998) 277-288
107. Hassan S.S.M., and Rechnitz G.A. Determination of glutathione and glutathione reductase with a silver sulfide membrane electrode. Anal. Chem. 54 (1982) 1972-1976
108. Jones D.P., Carlson J.L., Samiec P.S., Sternberg Jr. P., Mody Jr. V.C., Reed R.L., and Brown L.A. Glutathione measurement in human plasma. Evaluation of sample collection, storage and derivatization conditions for analysis of dansyl derivatives by HPLC. Clin. Chim. Acta 275 (1998) 175-184
109. Russo A., DeGraff W., Friedman N., and Mitchell J.B. Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs. Cancer Res. 46 (1986) 2845-2848
110. Ilangovan G., Li H.Q., Zweier J.L., and Kuppusamy P. In vivo measurement of tumor redox environment using EPR spectroscopy. Mol. Cell. Biochem. 234 (2002) 393-398
111. Neu M., Germershaus O., Mao S., Voigt K.H., Behe M., and Kissel T. Crosslinked nanocarriers based upon poly(ethylene imine) for systemic plasmid delivery: in vitro characterization and in vivo studies in mice. J. Control. Release 118 (2007) 370-380
112. Kommareddy S., and Amiji M. Poly(ethylene glycol)-modified thiolated gelatin nanoparticles for glutathione-responsive intracellular DNA delivery. Nanomedicine 3 (2007) 32-42
113. Kommareddy S., and Amiji M. Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione. Bioconjug. Chem. 16 (2005) 1423-1432
114. Wang Y., Chen P., and Shen J. The development and characterization of a glutathione-sensitive cross-linked polyethylenimine gene vector. Biomaterials 27 (2006) 5292-5298
115. Carlisle R.C., Etrych T., Briggs S.S., Preece J.A., Ulbrich K., and Seymour L.W. Polymer-coated polyethylenimine/DNA complexes designed for triggered activation by intracellular reduction. J. Gene Med. 6 (2004) 337-344
116. Hong R., Han G., Fernandez J.M., Kim B.-J., Forbes N.S., and Rotello V.M. Glutathione-mediated delivery and release using monolayer protected nanoparticle carriers. J. Am. Chem. Soc. 128 (2006) 1078-1079
117. Kakizawa Y., Harada A., and Kataoka K. Glutathione-sensitive stabilization of block copolymer micelles composed of antisense DNA and thiolated poly(ethylene glycol)-block-poly(l-lysine): a potential carrier for systemic delivery of antisense DNA. Biomacromolecules 2 (2001) 491-497
118. Laemmli U.K. Characterization of DNA condensates induced by poly(ethylene oxide) and polylysine. Proc. Natl. Acad. Sci. U. S. A. 72 (1975) 4288-4292
119. Tannock I.F., and Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 49 (1989) 4373-4384
120. Gerweck L.E., Vijayappa S., and Kozin S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol. Cancer Ther. 5 (2006) 1275-1279
121. Har-el Y.E., and Kato Y. Intracellular delivery of nanocarriers for cancer therapy. Curr. Nanosci. 3 (2007) 329-338
122. Murphy R., Powers S., and Cantor C. Endosome pH measured in single cells by dual fluorescence flow cytometry: rapid acidification of insulin to pH 6. J. Cell Biol. 98 (1984) 1757-1762
123. Helmlinger G., Yuan F., Dellian M., and Jain R.K. Interstitial pH and pO(2) gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat. Med. 3 (1997) 177-182
124. Dreher M.R., Liu W., Michelich C.R., Dewhirst M.W., Yuan F., and Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl. Cancer Inst. 98 (2006) 335-344
125. Straubinger R.M., Duzgunes N., and Papahadjopoulos D. pH-sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules. Febs Lett. 179 (1985) 148-154
126. Gruner S.M., and Jain M.K. X-ray-diffraction demonstrates that phosphatidyldiacylglycerol and phosphatidylcholesterol are not lamellar above the main transition-temperature. Biochim. Biophys. Acta 818 (1985) 352-355
127. Harper P.E., Mannock D.A., Lewis R.N.A.H., McElhaney R.N., and Gruner S.M. X-ray diffraction structures of some phosphatidylethanolamine lamellar and inverted hexagonal phases. Biophys. J. 81 (2001) 2693-2706
128. de Oliveira M.C., Rosilio V., Lesieur P., Bourgaux C., Couvreur P., Ollivon M., and Dubernet C. pH-sensitive liposomes as a carrier for oligonucleotides: a physico-chemical study of the interaction between DOPE and a 15-mer oligonucleotide in excess water. Biophys. Chemist. 87 (2000) 127-137
129. Sudimack J.J., Guo W.J., Tjarks W., and Lee R.J. A novel pH-sensitive liposome formulation containing oleyl alcohol. Biochim. Biophys. Acta 1564 (2002) 31-37
130. Kono K., Zenitani K., and Takagishi T. Novel pH-sensitive liposomes - liposomes bearing a poly(ethylene glycol) derivative with carboxyl groups. Biochim. Biophys. Acta 1193 (1994) 1-9
131. Guo W.J., Gosselin M.A., and Lee R.J. Characterization of a novel diolein-based LPDII vector for gene delivery. J. Control. Release 83 (2002) 31-37
132. Stevens M.M., Flynn N.T., Wang C., Tirrell D.A., and Langer R. Coiled-coil peptide-based assembly of gold nanoparticles. Adv. Mater. 16 (2004) 915-918
133. Ryadnov M.G., Ceyhan B., Niemeyer C.M., and Woolfson D.N. "Belt and braces": a peptide-based linker system of de novo design. J. Am. Chem. Soc. 125 (2003) 9388-9394
134. Li W.J., Nicol F., and Szoka F.C. GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery. Adv. Drug Deliv. Rev. 56 (2004) 967-985
135. Haas D.H., and Murphy R.M. Design of a pH-sensitive pore-forming peptide with improved performance. J. Pept. Res. 63 (2004) 9-16
136. Wyman T.B., Nicol F., Zelphati O., Scaria P.V., Plank C., and Szoka F.C. Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry 36 (1997) 3008-3017
137. Asayama S., Kato H., Kawakami H., and Nagaoka S. Carboxymethyl poly(l-histidine) as a new pH-sensitive polypeptide at endosomal/lysosomal pH. Polym. Adv. Technol. 18 (2007) 329-333
138. Asayama S., Sudo M., Nagaoka S., and Kawakami H. Carboxymethyl poly(l-histidine) as a new pH-sensitive polypeptide to enhance polyplex gene delivery. Mol. Pharm. 5 (2008) 898-901
139. Torchilin V., Levchenko T.S., Lukyanov A.N., Khaw B.A., Klibanov A.L., Rammohan R., Samokhin G.P., and Whiteman K.R. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim. Biophys. Acta. 1511 (2001) 397-411
140. Veronese F.M., and Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today 10 (2005) 1451-1458
141. Tyagi M., Rusnati M., Presta M., and Giacca M. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J. Biol. Chem. 276 (2001) 3254-3261
142. Jiang X.M., Fitzgerald M., Grant C.M., and Hogg P.J. Redox control of exofacial protein thiols/disulfides by protein disulfide isomerase. J. Biol. Chem. 274 (1999) 2416-2423
143. Ishida T., Kirchmeier M.J., Moase E.H., Zalipsky S., and Allen T.M. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim. Biophys. Acta. 1515 (2001) 144-158
144. Sonawane N.D., Szoka Jr. F.C., and Verkman A.S. Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J. Biol. Chem. 278 (2003) 44826-44831
145. Goormaghtigh E., De Meutter J., Szoka F., Cabiaux V., Parente R.A., and Ruysschaert J.M. Secondary structure and orientation of the amphipathic peptide GALA in lipid structures. An infrared-spectroscopic approach. Eur. J. Biochem. 195 (1991) 421-429
146. Subbarao N.K., Parente R.A., Szoka Jr. F.C., Nadasdi L., and Pongracz K. pH-dependent bilayer destabilization by an amphipathic peptide. Biochemistry 26 (1987) 2964-2972
147. Volk L.D., Flister M.J., Bivens C.M., Stutzman A., Desai N., Trieu V., and Ran S. Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. Neoplasia 10 (2008) 613-623
148. MacKay J.A., Li W., Huang Z., Dy E.E., Huynh G., Tihan T., Collins R., Deen D.F., and Szoka F.C. HIV TAT peptide modifies the distribution of DNA nanolipoparticles following convection-enhanced delivery. Molec. Ther. 16 (2008) 893-900
149. Gratton J.P., Yu J., Griffith J.W., Babbitt R.W., Scotland R.S., Hickey R., Giordano F.J., and Sessa W.C. Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo. Nat. Med. 9 (2003) 357-362
150. Eguchi A., Akuta T., Okuyama H., Senda T., Yokoi H., Inokuchi H., Fujita S., Hayakawa T., Takeda K., Hasegawa M., and Nakanishi M. Protein transduction domain of HIV-1 Tat protein promotes efficient delivery of DNA into mammalian cells. J. Biol. Chem. 276 (2001) 26204-26210
151. Temming K., Lacombe M., van der Hoeven P., Prakash J., Gonzalo T., Dijkers E.C., Orfi L., Keri G., Poelstra K., Molema G., and Kok R.J. Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology. Bioconjug. Chem. 17 (2006) 1246-1255
152. Karle I.L., and Urry D.W. Crystal structure of cyclic (APGVGV)2, an analog of elastin, and a suggested mechanism for elongation/contraction of the molecule. Biopolymers 77 (2005) 198-204
153. Long C.G., Braswell E., Zhu D., Apigo J., Baum J., and Brodsky B. Characterization of collagen-like peptides containing interruptions in the repeating Gly-X-Y sequence. Biochemistry 32 (1993) 11688-11695
154. Stevens M.M., Allen S., Sakata J.K., Davies M.C., Roberts C.J., Tendler S.J.B., Tirrell D.A., and Williams P.M. pH-dependent behavior of surface-immobilized artificial leucine zipper proteins. Langmuir 20 (2004) 7747-7752